中文摘要：

目的：探讨紫杉醇加铂类（PT组）和环磷酰胺加铂类（PC组）在卵巢上皮性癌初治患者中的疗效。方法：对1998年1月至2004年1月第四军医大学西京医院和第三军医大学大坪医院收治的78例卵巢上皮性癌术后患者进行回顾性分析，其中PT组36例，PC组42例，比较两组的近期疗效和3年存活率、无进展生存时间以及不良反应。结果：PT和PC方案的患者化疗有效率分别为77．8％和66．7％（P〈0．01），中位生存时间分别为29个月和23个月（P〈0．01），中位无进展生存时间分别为23个月和15个月（P〈0．01），3年存活率分别为41．7％和19．0％（P〈0．05）。在早期（Ⅰ期＋Ⅱ期）卵巢癌患者中，PT组和PC组中位生存时间和中位无进展生存时间差异无统计学意义，但中晚期（Ⅲ期＋Ⅳ期）患者PT组和PC组中位生存时间和中位无进展生存时间分别为25．4月和21．0月以及16．1月和7．9月（P〈0．05），有统计学意义，表明PT方案对中晚期患者可能更具有优势。PT组脱发和血液学毒性发生率高于PC组，而消化系统毒性和肝肾功损害发生率低于PC组。结论：卵巢癌的辅助化疗中，PT方案在化疗反应率、无进展生存时间及3年存活率均优于PC方案，对中晚期患者，前者的优势更为显著。

英文摘要：

Objective： To evaluate the efficacy between platinum plus taxinol （PT） and platinum plus Cyclophosphamide （PC） in the initial treatment of epithelia ovary cancer. Methods： A retrospective analysis in the initial treatment of 78 patients with epithelial ovarian cancer, who underwent optimal cytoreducitive operation and received regular postoperative chemotherapy from January 1998 to June 2004, was done.Of the 78 patients, 36 patients were in PT regimen group and 42 patients were in PC regimen group. The 3-year survival rate, the effective rate, tumor-free survival curves and main adverse events were compared between the two groups. Results： The effective rate in PT group and PC group was 77.8% and 66.7% respectively,with obvious differences between the two groups（P〈0.01）;the medians of over all survival time of the patients were 29 months and 23 months respectively in the two groups （P〈0.01）;the medians of progression-free survival time of the patients were 23 months and 15 months respectively in the two groups （P〈0.01）. The 3-year survival rate was 41.7% in PT group and 19.0% in PC group （P〈0.05）. In alopecia and hematology toxicity, the side-effects of PT group were stronger than those of PC group, but the digestive system toxicity, dysfunction of liver and kidney in PT group was slighter than those in PC group. Conclusion： In the adjuvant chemotherapy of ovary cancer patients, PT is clinically superior to PC in chemotherapy reactivity, progression-free survival time and 3-year survival rate, especially for middle-late ovarian carcinoma patients.